Log in
NASDAQ:ILMN

Illumina Stock Forecast, Price & News

$299.89
+13.58 (+4.74 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$279.88
Now: $299.89
$302.23
50-Day Range
$268.51
MA: $340.32
$399.33
52-Week Range
$196.78
Now: $299.89
$404.20
Volume4.34 million shs
Average Volume1.28 million shs
Market Capitalization$43.78 billion
P/E Ratio64.08
Dividend YieldN/A
Beta0.88
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens; and an agreement with HTG Molecular Diagnostics, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More
Illumina logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.54 billion
Cash Flow$6.98 per share
Book Value$31.38 per share

Profitability

Net Income$1.00 billion

Miscellaneous

Employees7,700
Market Cap$43.78 billion
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$299.89
+13.58 (+4.74 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Illumina (NASDAQ:ILMN) Frequently Asked Questions

How has Illumina's stock price been impacted by Coronavirus (COVID-19)?

Illumina's stock was trading at $246.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ILMN stock has increased by 21.9% and is now trading at $299.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Illumina?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 3 sell ratings, 8 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Illumina
.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for Illumina
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings results on Thursday, August, 6th. The life sciences company reported $0.62 EPS for the quarter, missing the Zacks' consensus estimate of $0.67 by $0.05. The life sciences company earned $633 million during the quarter, compared to analysts' expectations of $682.07 million. Illumina had a net margin of 20.67% and a return on equity of 19.13%. Illumina's quarterly revenue was down 24.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.35 EPS.
View Illumina's earnings history
.

What price target have analysts set for ILMN?

18 equities research analysts have issued 1 year target prices for Illumina's stock. Their forecasts range from $280.00 to $400.00. On average, they anticipate Illumina's stock price to reach $325.39 in the next year. This suggests a possible upside of 8.5% from the stock's current price.
View analysts' price targets for Illumina
.

Are investors shorting Illumina?

Illumina saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 3,910,000 shares, an increase of 10.5% from the August 15th total of 3,540,000 shares. Based on an average daily trading volume, of 859,400 shares, the days-to-cover ratio is presently 4.5 days. Approximately 2.7% of the shares of the company are short sold.
View Illumina's Short Interest
.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), salesforce.com (CRM), Adobe (ADBE), Visa (V), Micron Technology (MU) and Paypal (PYPL).

Who are Illumina's key executives?

Illumina's management team includes the following people:
  • Mr. Jay T. Flatley, Exec. Chairman (Age 66)
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)
  • Mr. Sam A. Samad, CFO & Sr. VP (Age 49)
  • Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)
  • Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48)

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.97%), Copper Rock Capital Partners LLC (1.59%), Nuveen Asset Management LLC (1.37%), Jennison Associates LLC (1.17%), Jackson Square Partners LLC (0.87%) and Sumitomo Mitsui Trust Holdings Inc. (0.78%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina
.

Which institutional investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including Verition Fund Management LLC, Sumitomo Mitsui Trust Holdings Inc., Nuveen Asset Management LLC, Toronto Dominion Bank, Bellevue Group AG, Jackson Square Partners LLC, Kornitzer Capital Management Inc. KS, and Tekla Capital Management LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina
.

Which institutional investors are buying Illumina stock?

ILMN stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, GUARDCAP ASSET MANAGEMENT Ltd, Bank of Montreal Can, William Blair Investment Management LLC, Nordea Investment Management AB, Natixis Advisors L.P., First Trust Advisors LP, and Envestnet Asset Management Inc..
View insider buying and selling activity for Illumina
.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $299.89.

How big of a company is Illumina?

Illumina has a market capitalization of $43.78 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]

This page was last updated on 9/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.